Helen Torley
Chief Executive Officer bei HALOZYME THERAPEUTICS, INC.
Vermögen: 28 Mio $ am 31.03.2024
Profil
Helen I. Torley bekleidet die Position des President, Chief Executive Officer & Director bei Halozyme Therapeutics, Inc. Sie ist auch im Vorstand von Quest Diagnostics, Inc. und Director & Member-Health Section Governing Board bei der Biotechnology Innovation Organization und Mitglied des Royal College of Physicians. In der Vergangenheit war sie Vice President & GM-United States Bone Health bei Amgen, Inc. und Chief Commercial Officer & Executive VP bei Onyx Pharmaceuticals, Inc. (eine Tochtergesellschaft von Amgen, Inc.), Vice President-Medical Affairs bei Novartis, Inc., Vice President-Medical Affairs bei Sandoz SA und Vice President-Cardiovascular & Metabolic Sales bei Bristol-Myers Squibb World Wide Medicines Group. Sie erhielt einen Bachelor-Abschluss von der University of Glasgow.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.02.2024 | 676 744 ( 0,53% ) | 28 Mio $ | 31.03.2024 |
Aktive Positionen von Helen Torley
| Unternehmen | Position | Beginn |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Chief Executive Officer | 06.01.2014 |
| ANTARES PHARMA, INC. | Director/Board Member | 24.05.2022 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Ehemalige bekannte Positionen von Helen Torley
| Unternehmen | Position | Ende |
|---|---|---|
| QUEST DIAGNOSTICS INCORPORATED | Director/Board Member | 18.05.2022 |
| RELYPSA INC | Director/Board Member | 01.09.2016 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Operating Officer | 15.12.2011 |
| AMGEN INC. | Corporate Officer/Principal | 01.01.2011 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2002 |
Ausbildung von Helen Torley
| University of Glasgow | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| QUEST DIAGNOSTICS INCORPORATED | Health Services |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Antares Pharma, Inc.
 Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ. | Health Technology |
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a private company based in San Francisco. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
| Sandoz SA |
